Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A10384 | Pages: NA | Charts: NA | Tables: NA |
Inhalers are also named as allergy spray or pump. Inhalers are mostly used for treatment and medication delivery for respiratory diseases including chronic obstructive pulmonary disease and asthma. Inhalers play a vital role in the management of patients with obstructive airway disease (OAD). Inhalers minimize medication in throat or mouth and the need for exact synchronization with actuation of the device. The digital inhaler is a device that delivers a specific amount of medication to the lungs, in the form of a short burst of aerosolized medicine that is self-administered by the patient through inhalation. Digital inhaler has built-in sensors that detect use of inhaler and measure inspiratory flow, according to the release and dose management. There are various types of digital dose inhaler available in the market such as metered dose inhaler (MDI) and dry powder inhaler (DPI). Out of which metered dose inhaler most widely used dose delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
COVID-19 Scenario Analysis:
To take care of infected population the demand for medical supplies is increasing. Respiratory support devices such as atomizer, life-support machine, oxygen generator, and monitor are among the majorly used medical devices in primary clinical treatment. Moreover, COVID-19 has led to a huge surge in demand for medical supplies such as personal protective equipment including masks, gloves, and protective eyeglasses. With rise in number of COVID-19 cases worldwide, the need for medical supplies keeps on rising among, both from healthcare professionals and civil population for precautionary measures. Manufacturers of these products have a chance to capitalize this increased demand of medical supplies to ensure adequate and continuous supply of personal protective equipment in the market.
The ongoing outbreak of COVID-19 pandemic impacted the medical device industry positively. It affect digital dose inhaler market. This increasing pandemic situation affect the supply chain and reduce the demand of digital dose inhaler devices which attributed to temporarily shutting down of industries and announcement of lockdown by government in various region
Globally, North America hold the largest market share and dominate overall digital dose inhaler market due to the increasing research and development activities, growing awareness regarding hi-tech respiratory devices, increasing incidence of respiratory disorders. However, the Asia Pacific is anticipated to expand market growth rate which attributed to increasing geriatric population, increases respiratory devices vertical, growing demand for advanced respiratory care devices, in addition, the presence of favourable government initiatives, such as “Make in India” campaign, which provides startup companies with subsidized land rates to launch their manufacturing units which help to expand the digital dose inhaler market in developing region. According to “WHO” report, in 2015, around 3 million deaths occur due to COPD across the globe. “WHO” also reported that more than 90% of the COPD deaths occurred in the developing countries.
The factors such as the increasing geriatric population, growing respiratory disorders of both, severe and mild forms, increasing demand for these new generation inhalation devices, rising demand for cost-effective medications, growing awareness amongst the people about the benefits of generic drugs, etc., are expected to significantly drive the digital dose inhaler market. However, the factors that restrain the growth of market such as high cost of medication and devices, lack of awareness amongst the people about advanced treatment and available devices for asthma, and reduce the investment in R&D activities. The opportunities available for digital dose inhaler market such as, increasing investment in R&D activities, developing advancement in manufacturing devices for asthma and providing cost effective medication for patient.
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications.
In 2017, “Glenmark Pharmaceuticals Limited”, launched as India’s first Digital Dose Inhaler such as “Digihaler”, for asthma and pulmonary disease patients. This inhaler provides accurate digital dose counter along with low dose warning indicator to allow asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy,
In 2018, “Novartis”, has launched “Symbicort”. This inhaler used to control and prevent the symptoms of asthma in adults and children at least 6 years old and also used to control the symptoms of chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema
In 2019, Propeller Health has launched “Diskus®” This product is used to control and prevent symptoms like wheezing and shortness of breath caused by asthma and ongoing lung disease such as chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema.
In 2019, “Teva Pharmaceutical Industries Ltd”. announced that the U.S. Food and Drug Administration (FDA) has approved “ProAir Digihaler” inhalation powder, the first and only digital inhaler with built-in sensors which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. ProAir Digihaler is used for the treatment or prevention of bronchospasm in patients aged four years and older with reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm (EIB) in patients aged four years and older.
Key benefits of the report:
Questions answered in the Digital Dose Inhaler Market research report:
Key Market Segments
Key Market Players
